Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

Stopped early

Conditions studied: Chronic Granulomatous Disease

In brief

The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Chronic Granulomatous Disease (CGD). The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

Key facts

Study ID

NCT05915897

Run by

Sanguine Biosciences

People needed

6

Starts

2023-05-23

Expected to finish

2024-03-25

Last updated by the study team

2024-04-18

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant is willing and able to provide written informed consent
• The participant is willing and able to provide appropriate photo identification
• Participants aged 18 to 85
• Participants have been diagnosed with Chronic Granulomatous Disease (CGD)
• Subjects who have a confirmed p47phox CGD mutation or Subjects who have a confirmed X-linked CGD mutation

You may not qualify if…

• Participants who are pregnant or are nursing
• Participants with a known history of HIV, hepatitis, or other infectious diseases
• Participants who have taken an investigational product in the last 30 days
• Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

Where it is running

• Sanguine BioSciences, Inc. — Woburn, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.